TY - JOUR A1 - Pinter, Andreas A1 - Schwarz, Peter A1 - Gerdes, Sascha A1 - Simon, Jan C. A1 - Saalbach, Anja A1 - Rush, James A1 - Melzer, Nima A1 - Kramps, Thomas A1 - Häberle, Benjamin A1 - Reinhardt, Maximilian T1 - Biologic treatment in combination with lifestyle intervention in moderate to severe plaque psoriasis and concomitant metabolic syndrome: rationale and methodology of the METABOLyx randomized controlled clinical trial T2 - Nutrients N2 - Inflammatory diseases including psoriasis are associated with metabolic and cardiovascular comorbidities, including obesity and metabolic syndrome. Obesity is associated with greater psoriasis disease severity and reduced response to treatment. Therefore, targeting metabolic comorbidities could improve patients’ health status and psoriasis-specific outcomes. METABOLyx is a randomized controlled trial evaluating the combination of a lifestyle intervention program with secukinumab treatment in psoriasis. Here, the rationale, methodology and baseline patient characteristics of METABOLyx are presented. A total of 768 patients with concomitant moderate to severe plaque psoriasis and metabolic syndrome were randomized to secukinumab 300 mg, or secukinumab 300 mg plus a tailored lifestyle intervention program, over 24 weeks. A substudy of immunologic and metabolic biomarkers is ongoing. The primary endpoint of METABOLyx is PASI90 response at week 24. Other endpoints include patient-reported outcomes and safety. METABOLyx represents the first large scale clinical trial of an immunomodulatory biologic in combination with a standardized lifestyle intervention. KW - psoriasis KW - obesity KW - metabolic syndrome KW - secukinumab KW - inflammation Y1 - 2021 UR - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/62181 UR - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-621818 SN - 2072-6643 N1 - The METABOLyx study is sponsored by Novartis Pharma GmbH, Nuremberg, Germany. VL - 13 IS - 9, art. 3015 SP - 1 EP - 14 PB - MDPI CY - Basel ER -